deoxyartemisinin and artenimol

Dihydroartemisinin (DHA, 1), a sesquiterpene endoperoxide derived from artemisinin, has shown potent antimalarial and anticancer activities. Microbial transformation of DHA by Absidia coerulea and Penicillium chrysogenum yielded one new (3) and four known metabolites (2, 4-6). The chemical structures of these compounds were identified as deoxydihydroartemisinin (2), 8α-hydroxydeoxyartemisinin (3), deoxyartemisinin (4), 9α-hydroxyartemethin-I (5) and 3α-hydroxydeoxydihydroartemisinin (6) using spectroscopic analyses. Among them, compounds 3 and 4 are artemisinin analogues, which were achieved by unusual oxidation at C-12 position. Biotransformation of DHA by microorganisms was an effective approach to obtain new derivatives of DHA.

Topics: Absidia; Antimalarials; Artemisinins; Biotransformation; Molecular Structure; Oxidation-Reduction; Penicillium chrysogenum

Artemisinin derivatives such as dihydroartemisinin (DHA) induce significant depletion of early embryonic erythroblasts in animal models. We have reported previously that DHA specifically targets pro-erythroblasts and basophilic erythroblasts, when human CD34+ stem cells are differentiated toward the erythroid lineage, indicating that a window of susceptibility to artemisinins may exist also in human developmental erythropoiesis during pregnancy. To better investigate the toxicity of artemisinin derivatives, the structure-activity relationship was evaluated against the K562 leukaemia cell line, used as a model for differentiating early human erythroblasts. All artemisinins derivatives, except deoxyartemisinin, inhibited both spontaneous and induced erythroid differentiation, confirming that the peroxide bridge is responsible for the erythro-toxicity. On the contrary, cell growth was markedly reduced by DHA, artemisone and artesunate but not by artemisinin, 10-deoxoartemisinin or deoxy-artemisinin. The substituent at position C-10 is responsible only for the anti-proliferative effect, since 10-deoxoartemisinin did not reduce cell growth but arrested the differentiation of K562 cells. In particular, the results showed that DHA resulted the most potent and rapidly acting compound of the drug family, causing (i) the decreased expression of GpA surface receptors and the down regulation the γ-globin gene; (ii) the alteration of S phase of cell cycle and (iii) the induction of programmed cell death of early erythroblasts in a dose dependent manner within 24h. In conclusion, these findings confirm that the active metabolite DHA is responsible for the erythro-toxicity of most of artemisinins used in therapy. Thus, as long as no further clinical data are available, current WHO recommendations of avoiding malaria treatment with artemisinins during the first trimester of pregnancy remain valid.

Topics: Artemisinins; Cell Cycle; Cell Differentiation; Erythroid Cells; Flow Cytometry; Humans; K562 Cells; Reverse Transcriptase Polymerase Chain Reaction; Structure-Activity Relationship

A novel class of artemisinin analogs, N-alkyl-11-aza-9-desmethylartemisinins 17-29, were synthesized via ozonolysis and acid-catalyzed cyclization of precursor amides 5-16. These amides were prepared through condensation of an activated ester of the known intermediate acid 2 with the corresponding primary amine. The analogs were tested in vitro against W-2 and D-6 strains of Plasmodium falciparum and found in some cases to be more active than artemisinin. A comparison of the in vitro testing methods of Milhous and Makler was conducted and gave similar relative antimalarial activities for these artemisinin analogs. Log P values were determined for most of the compounds, but no apparent correlation between log P and in vitro activity was found.

Topics: Animals; Antimalarials; Artemisinins; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Erythrocytes; Humans; Molecular Structure; Plasmodium falciparum; Sesquiterpenes; Structure-Activity Relationship